This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05860296
Recruitment Status : Recruiting
First Posted : May 16, 2023
Last Update Posted : February 29, 2024
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
SignalChem Lifesciences Corporation

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2027